Literature DB >> 24834396

Rhabdomyolysis, compartment syndrome and thermal injury.

Yusuf Kenan Coban1.   

Abstract

Rhabdomyolysis (RML) after electrical burns and crush injuries is a well-known clinical entity, but its occurrence following thermal injury has not gained so much attention. Capillary leak syndrome and following polycompartmental syndrome are devastating end results of major thermal injuries. In the current review, polycompartment syndrome within the clinical picture of systemic oedema and its relationship to RML is discussed along with its management and prevention.

Entities:  

Keywords:  Capillary leak syndrome; Rhabdomyolysis; Thermal injury

Year:  2014        PMID: 24834396      PMCID: PMC4021149          DOI: 10.5492/wjccm.v3.i1.1

Source DB:  PubMed          Journal:  World J Crit Care Med        ISSN: 2220-3141


  42 in total

1.  Grading of severity of the condition in burn patients by serum protein and albumin/globulin studies.

Authors:  Pramod Kumar
Journal:  Ann Plast Surg       Date:  2010-07       Impact factor: 1.539

2.  Comparison of two fluid-management strategies in acute lung injury.

Authors:  Herbert P Wiedemann; Arthur P Wheeler; Gordon R Bernard; B Taylor Thompson; Douglas Hayden; Ben deBoisblanc; Alfred F Connors; R Duncan Hite; Andrea L Harabin
Journal:  N Engl J Med       Date:  2006-05-21       Impact factor: 91.245

3.  Analysis of altered capillary pressure and permeability after thermal injury.

Authors:  R M Pitt; J C Parker; G J Jurkovich; A E Taylor; P W Curreri
Journal:  J Surg Res       Date:  1987-06       Impact factor: 2.192

4.  Drugs, coma, and myoglobinuria.

Authors:  A S Penn; L P Rowland; D W Fraser
Journal:  Arch Neurol       Date:  1972-04

5.  Hypoalbuminemia in the first 24h of admission is associated with organ dysfunction in burned patients.

Authors:  Roberto Eljaiek; Marc-Jacques Dubois
Journal:  Burns       Date:  2012-06-07       Impact factor: 2.744

6.  Hydroxyethylstarch supplementation in burn resuscitation--a prospective randomised controlled trial.

Authors:  E Vlachou; P Gosling; N S Moiemen
Journal:  Burns       Date:  2010-06-16       Impact factor: 2.744

7.  Serum creatine kinase levels and renal function measures in exertional muscle damage.

Authors:  Priscilla M Clarkson; Amy K Kearns; Pierre Rouzier; Richard Rubin; Paul D Thompson
Journal:  Med Sci Sports Exerc       Date:  2006-04       Impact factor: 5.411

8.  Early albumin use improves mortality in difficult to resuscitate burn patients.

Authors:  Sandra H Park; Mark R Hemmila; Wendy L Wahl
Journal:  J Trauma Acute Care Surg       Date:  2012-11       Impact factor: 3.313

9.  Adequate resuscitation of burn patients may not be measured by urine output and vital signs.

Authors:  D J Dries; K Waxman
Journal:  Crit Care Med       Date:  1991-03       Impact factor: 7.598

10.  Interleukin-6 down-regulates expressions of the aldolase B and albumin genes through a pathway involving the activation of tyrosine kinase.

Authors:  Y Huang; H Shinzawa; H Togashi; T Takahashi; T Kuzumaki; K Otsu; K Ishikawa
Journal:  Arch Biochem Biophys       Date:  1995-07-10       Impact factor: 4.013

View more
  3 in total

1.  Large vessel vasculitis with rare presentation of acute rhabdomyolysis: A case report and review of literature.

Authors:  Lan-Jun Fu; Shou-Ci Hu; Wen Zhang; Li-Qing Ye; Hong-Bo Chen; Xiao-Jun Xiang
Journal:  World J Clin Cases       Date:  2022-05-06       Impact factor: 1.534

2.  Primary hypoparathyroidism accompanied by rhabdomyolysis induced by infection: A case report.

Authors:  Li-Na Ding; Yi Wang; Jun Tian; Li-Fang Ye; Shi Chen; Shi-Min Wu; Wen-Bin Shang
Journal:  World J Clin Cases       Date:  2019-10-06       Impact factor: 1.337

Review 3.  Therapeutic Modulation of the Host Defense by Hemoadsorption with CytoSorb®-Basics, Indications and Perspectives-A Scoping Review.

Authors:  Thomas Köhler; Elke Schwier; Janina Praxenthaler; Carmen Kirchner; Dietrich Henzler; Claas Eickmeyer
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.